Sebastian Galeano, Carmem Bonfim, Amado Karduss, Gregorio Jaimovich, Andrés Gómez-De León, Gustavo Bettarello, Anderson Simione, Cinthya Correa, Helen Baldomero, Daniel Neumann, Ana Lisa Basquiera, Mariano Berro, Guillermina Remaggi, Ariel Amaru, Fernando Barroso, Adriana Seber, Francisco Barriga, Julia Palma, Bárbara Puga, Matías Sánchez, Juan Manuel Herrera, Calixto Hernández, David Gómez-Almaguer, Félix Gaytán Morales, Guillermo J Ruiz-Argüelles, Ninotzka Mendoza, María Liz Benítez, Alfredo Wong, Carolina Pagés, Marcos Hernández, Dietger Niederwieser, Damiano Rondelli, Cristóbal Frutos
{"title":"拉丁美洲骨髓移植协会（LABMT） 2019-2022年活动调查结果：COVID-19大流行的影响和相关单倍体捐赠者的增加。","authors":"Sebastian Galeano, Carmem Bonfim, Amado Karduss, Gregorio Jaimovich, Andrés Gómez-De León, Gustavo Bettarello, Anderson Simione, Cinthya Correa, Helen Baldomero, Daniel Neumann, Ana Lisa Basquiera, Mariano Berro, Guillermina Remaggi, Ariel Amaru, Fernando Barroso, Adriana Seber, Francisco Barriga, Julia Palma, Bárbara Puga, Matías Sánchez, Juan Manuel Herrera, Calixto Hernández, David Gómez-Almaguer, Félix Gaytán Morales, Guillermo J Ruiz-Argüelles, Ninotzka Mendoza, María Liz Benítez, Alfredo Wong, Carolina Pagés, Marcos Hernández, Dietger Niederwieser, Damiano Rondelli, Cristóbal Frutos","doi":"10.1038/s41409-025-02600-7","DOIUrl":null,"url":null,"abstract":"<p><p>A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors.\",\"authors\":\"Sebastian Galeano, Carmem Bonfim, Amado Karduss, Gregorio Jaimovich, Andrés Gómez-De León, Gustavo Bettarello, Anderson Simione, Cinthya Correa, Helen Baldomero, Daniel Neumann, Ana Lisa Basquiera, Mariano Berro, Guillermina Remaggi, Ariel Amaru, Fernando Barroso, Adriana Seber, Francisco Barriga, Julia Palma, Bárbara Puga, Matías Sánchez, Juan Manuel Herrera, Calixto Hernández, David Gómez-Almaguer, Félix Gaytán Morales, Guillermo J Ruiz-Argüelles, Ninotzka Mendoza, María Liz Benítez, Alfredo Wong, Carolina Pagés, Marcos Hernández, Dietger Niederwieser, Damiano Rondelli, Cristóbal Frutos\",\"doi\":\"10.1038/s41409-025-02600-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.</p>\",\"PeriodicalId\":9126,\"journal\":{\"name\":\"Bone Marrow Transplantation\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bone Marrow Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41409-025-02600-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41409-025-02600-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors.
A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.
期刊介绍：
Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation.
The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
